Ultragenyx to Participate in Investor Conferences in September
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on developing therapies for rare genetic diseases, has announced its participation in three upcoming investor conferences in September 2024:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
- Cantor Global Healthcare Conference on September 17
- Bank of America Global Healthcare Conference on September 18
Key executives, including CEO Emil Kakkis, CFO Howard Horn, and CMO Eric Crombez, will participate in fireside chats and host one-on-one meetings. Live and archived webcasts of the fireside chats will be available on the company's investor relations website. Ultragenyx is committed to developing novel products for serious rare and ultrarare genetic diseases, with a diverse portfolio of approved therapies and product candidates.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), un'azienda biofarmaceutica focalizzata sullo sviluppo di terapie per malattie genetiche rare, ha annunciato la sua partecipazione a tre conferenze per investitori in programma a settembre 2024:
- 22a Conferenza Annuale sulla Salute Globale di Morgan Stanley il 4 settembre
- Conferenza sulla Salute Globale di Cantor il 17 settembre
- Conferenza sulla Salute Globale di Bank of America il 18 settembre
I principali dirigenti, tra cui il CEO Emil Kakkis, il CFO Howard Horn e il CMO Eric Crombez, parteciperanno a discussioni informali e ospiteranno incontri one-on-one. Le trasmissioni in diretta e registrate delle discussioni informali saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda. Ultragenyx è impegnata nello sviluppo di prodotti innovativi per gravi malattie genetiche rare e ultrarare, con un portafoglio diversificato di terapie approvate e candidati a prodotti.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una empresa biofarmacéutica centrada en el desarrollo de terapias para enfermedades genéticas raras, ha anunciado su participación en tres conferencias para inversores que se llevarán a cabo en septiembre de 2024:
- 22ª Conferencia Anual de Salud Global de Morgan Stanley el 4 de septiembre
- Conferencia de Salud Global de Cantor el 17 de septiembre
- Conferencia de Salud Global de Bank of America el 18 de septiembre
Los principales ejecutivos, incluidos el CEO Emil Kakkis, el CFO Howard Horn y el CMO Eric Crombez, participarán en charlas informales y organizarán reuniones uno a uno. Se podrá acceder a transmisiones en vivo y grabadas de las charlas informales en el sitio web de relaciones con inversores de la empresa. Ultragenyx se compromete a desarrollar productos novedosos para enfermedades genéticas raras y ultrararas graves, con un portafolio diverso de terapias aprobadas y candidatos a productos.
울트라제닉스 제약회사(나스닥: RARE)는 희귀 유전 질환 치료제 개발에 집중하는 생명공학 회사로, 2024년 9월에 열릴 예정인 세 가지 투자자 회의에 참여한다고 발표했습니다:
- 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스 9월 4일
- 칸토 글로벌 헬스케어 컨퍼런스 9월 17일
- 뱅크 오브 아메리카 글로벌 헬스케어 컨퍼런스 9월 18일
CEO 에밀 카키스, CFO 하워드 혼, CMO 에릭 크롬베즈를 포함한 주요 경영진이 대화형 세션에 참석하고 일대일 회의를 개최할 예정입니다. 대화형 세션의 실시간 및 녹화된 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공될 것입니다. 울트라제닉스는 심각한 희귀 및 초희귀 유전 질환을 위한 새로운 제품 개발에 최선을 다하고 있으며, 다양한 승인 치료제 및 제품 후보군을 보유하고 있습니다.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), une société biopharmaceutique axée sur le développement de thérapies pour les maladies génétiques rares, a annoncé sa participation à trois conférences d'investisseurs à venir en septembre 2024 :
- 22ème Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 4 septembre
- Conférence Mondiale sur la Santé de Cantor le 17 septembre
- Conférence Mondiale sur la Santé de Bank of America le 18 septembre
Des cadres clés, y compris le PDG Emil Kakkis, le CFO Howard Horn et le CMO Eric Crombez, participeront à des discussions informelles et organiseront des réunions en tête-à-tête. Les webinaires en direct et archivés des discussions informelles seront disponibles sur le site web des relations avec les investisseurs de l'entreprise. Ultragenyx est engagée dans le développement de produits novateurs pour des maladies génétiques rares et ultraraires graves, avec un portefeuille diversifié de thérapies approuvées et de candidats produits.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für seltene genetische Erkrankungen konzentriert, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2024 angekündigt:
- 22. jährliche globale Gesundheitskonferenz von Morgan Stanley am 4. September
- Globale Gesundheitskonferenz von Cantor am 17. September
- Globale Gesundheitskonferenz von Bank of America am 18. September
Wichtige Führungskräfte, darunter CEO Emil Kakkis, CFO Howard Horn und CMO Eric Crombez, werden an informellen Gesprächen teilnehmen und Einzelgespräche führen. Live- und archivierte Webcasts der informellen Gespräche werden auf der Investor-Relations-Website des Unternehmens verfügbar sein. Ultragenyx hat sich der Entwicklung neuartiger Produkte für schwere seltene und ultrarare genetische Erkrankungen verschrieben und verfügt über ein vielfältiges Portfolio genehmigter Therapien und Produktkandidaten.
- None.
- None.
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
Cantor Global Healthcare Conference on September 17
Bank of America Global Healthcare Conference on September 18
NOVATO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY)
- Wednesday, September 4, 2024, Emil Kakkis, M.D., Ph.D., CEO and President, will participate in a fireside chat and host 1x1 meetings.
Cantor Global Healthcare Conference (New York, NY)
- Tuesday, September 17, 2024, Emil Kakkis and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.
Bank of America Global Healthcare Conference (London, UK)
- Wednesday, September 18, 2024, Eric Crombez, M.D., Chief Medical Officer and Joshua Higa, Vice President, Investor Relations, will participate in a fireside chat and host 1x1 meetings.
The live and archived webcast of the fireside chats will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
What investor conferences will Ultragenyx (RARE) attend in September 2024?
Who will represent Ultragenyx (RARE) at these investor conferences?
How can investors access Ultragenyx's (RARE) fireside chats from these conferences?
What is Ultragenyx's (RARE) primary focus as a biopharmaceutical company?
